Edition:
India

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

12.44HKD
16 Aug 2019
Change (% chg)

HK$0.48 (+4.01%)
Prev Close
HK$11.96
Open
HK$12.02
Day's High
HK$12.66
Day's Low
HK$11.92
Volume
41,247,474
Avg. Vol
31,365,919
52-wk High
HK$21.20
52-wk Low
HK$9.90

Latest Key Developments (Source: Significant Developments)

CSPC Pharmaceutical Group Says New Target Anti-Tumor Drug Granted Clinical Trial Approval
Monday, 29 Jul 2019 

July 29 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::NEW TARGET ANTI-TUMOR DRUG "SYHA1807" GRANTED CLINICAL TRIAL APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION.  Full Article

CSPC Pharmaceutical Group Sees Jan-June Net Profit Attributable Increased By 12% To 30% Of Cspc Innovation Pharmaceutical Co
Friday, 12 Jul 2019 

July 12 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::SEES JAN-JUNE NET PROFIT ATTRIBUTABLE INCREASED BY 12% TO 30% OF CSPC INNOVATION PHARMACEUTICAL CO.  Full Article

CSPC Pharmaceutical Group Says Ticagrelor Tablets Granted Drug Registration Approval
Thursday, 13 Jun 2019 

June 13 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::TICAGRELOR TABLETS GRANTED DRUG REGISTRATION APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

CSPC Pharmaceutical Says Clopidogrel Bisulfate Tablets Granted Drug Registration Approval
Monday, 10 Jun 2019 

June 10 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CLOPIDOGREL BISULFATE TABLETS GRANTED DRUG REGISTRATION APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

CSPC Pharmaceutical Group Posts Qtrly Profit Attributable Of RMB951.8 Mln
Tuesday, 21 May 2019 

May 21 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::QTRLY PROFIT ATTRIBUTABLE RMB951.8 MILLION VERSUS RMB738.8 MILLION .QTRLY TOTAL REVENUE RMB5.49 BILLION VERSUS RMB4.37 BILLION .  Full Article

CSPC Pharmaceutical Group Posts FY Profit Attributable Of HK$3.65 Bln
Monday, 18 Mar 2019 

March 18 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::FY PROFIT ATTRIBUTABLE HK$3.65 BILLION VERSUS HK$2.77 BILLION.FY REVENUE HK$21.03 BILLION VERSUS HK$15.46 BILLION.DECLARED A FINAL DIVIDEND PER SHARE OF HK18 CENTS.  Full Article

CSPC Pharmaceutical Submitted New Drug Application To U.S. FDA For Levoamlodipine Maleate Tablets
Tuesday, 5 Mar 2019 

March 5 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::SUBMITTED NEW DRUG APPLICATION TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS FOR TREATMENT OF HYPERTENSION.  Full Article

CSPC Pharmaceutical Says Cetrain Financial Media Reported Co Indicated 20 Pct-30 Pct Profit Growth For FY19
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CSPC PHARMACEUTICAL SAYS CETRAIN FINANCIAL MEDIA REPORTED THAT COMPANY INDICATED A TARGET GUIDANCE OF 20%-30% PROFIT GROWTH OF GROUP FOR FY 2019.BOARD STATES THAT ANALYST REPORTS FAIRLY REFLECT CURRENT VIEW OF MANAGEMENT.  Full Article

CSPC Pharmaceutical Group'S Unit Enters Agreement With I-Mab Biopharma (Shanghai) Co
Monday, 17 Dec 2018 

Dec 17 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::UNIT ENTERED INTO AN AGREEMENT WITH I-MAB BIOPHARMA (SHANGHAI) CO., LTD..CSPC BAIKE AGREED TO PAY UPFRONT PAYMENT OF RMB15 MILLION & DEVELOPMENT MILESTONE PAYMENTS OF UP TO RMB135 MILLION TO I-MAB.DEAL FOR LICENSING & COMMERCIALIZATION OF LONG-ACTING RECOMBINANT GLP-1 FC FUSION PROTEIN (TG103) FOR INJECTION DEVELOPED BY I-MAB.  Full Article

CSPC Pharmaceutical Group's "Amoxicillin Capsules" Granted Approval By NMPA
Monday, 26 Nov 2018 

Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::GROUP'S "AMOXICILLIN CAPSULES" GRANTED APPROVAL BY NMPA FOR PASSING CONSISTENCY EVALUATION.  Full Article